Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Western Blotting for Protein Expression – V 2.0

Posted on By


Biosimilars: SOP for Western Blotting for Protein Expression – V 2.0


Standard Operating Procedure for Western Blotting for Protein Expression in Biosimilar Cell Clones

Department Biosimilars
SOP No. SOP/BS/014/2025
Supersedes SOP/BS/014/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the standardized procedure for detecting and analyzing biosimilar protein expression in cell lysates using SDS-PAGE followed by Western blotting during clone evaluation and selection.

2. Scope

This SOP is applicable to research and analytical staff involved in screening and confirming protein expression in cell-based biosimilar production systems using immunoblotting techniques.

3. Responsibilities

  • Analytical Scientist: Performs protein extraction, SDS-PAGE, blotting, and detection.
  • Lab Technician: Assists in reagent preparation and operation of blotting apparatus.
  • QA Officer: Verifies blotting data and ensures procedural documentation is complete.
See also  Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) - V 2.0

4. Accountability

The Head of Analytical Development is accountable for ensuring the Western blotting process is performed accurately and results are validated and recorded per regulatory guidelines.

5. Procedure

5.1 Sample Preparation

  1. Harvest cells and wash with PBS.
  2. Lyse cells using RIPA buffer supplemented with protease inhibitors.
  3. Centrifuge at 13,000 rpm for 15 minutes at 4°C and collect supernatant.
  4. Quantify protein concentration using BCA or Bradford assay.

5.2 SDS-PAGE Electrophoresis

  1. Prepare 10–12% polyacrylamide gels depending on target protein size.
  2. Mix equal volumes of sample (20–40 µg protein) with 2X Laemmli buffer and heat at 95°C for 5 minutes.
  3. Load molecular weight marker and samples into gel wells.
  4. Run gel at 100–120V until dye front reaches the bottom.

5.3 Transfer to Membrane

  1. Assemble gel and PVDF/nitrocellulose membrane in blotting cassette.
  2. Transfer proteins at 100V for 1 hour or 30V overnight at 4°C.
  3. Confirm transfer by Ponceau S staining if required.
See also  Biosimilars: SOP for Colony Screening and Expression Analysis - V 2.0

5.4 Blocking and Antibody Incubation

  1. Block membrane with 5% skim milk or BSA in TBST for 1 hour at room temperature.
  2. Incubate with primary antibody (e.g., anti-biosimilar protein) in blocking buffer for 2 hours or overnight at 4°C.
  3. Wash membrane 3× with TBST, 5 minutes each wash.
  4. Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature.
  5. Repeat washing step post-secondary antibody incubation.

5.5 Detection and Documentation

  1. Develop blot using chemiluminescent substrate.
  2. Capture signal using gel documentation system or X-ray film.
  3. Record exposure time, band intensity, and molecular weight in Western Blot Analysis Log (Annexure-1).

6. Abbreviations

  • SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
  • HRP: Horseradish Peroxidase
  • TBST: Tris Buffered Saline with Tween 20
  • BSA: Bovine Serum Albumin

7. Documents

  1. Western Blot Analysis Log (Annexure-1)
  2. Antibody and Reagent Inventory Sheet (Annexure-2)
See also  Biosimilars: SOP for Productivity Testing in Small-Scale Cultures - V 2.0

8. References

  • ICH Q6B – Specifications: Test Procedures for Biotechnological Products
  • WHO Guidelines on Biosimilar Characterization
  • CDSCO Analytical Method Validation Guidance

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Western Blot Analysis Log

Date Clone ID Protein Target Band Size (kDa) Intensity Remarks Operator
03/05/2025 CL-BS-014 rhEPO 34 Strong Expected size observed Sunita Reddy

Annexure-2: Antibody and Reagent Inventory Sheet

Item Lot No. Expiry Storage Stock Qty
Anti-rhEPO Antibody AB2345 10/2026 2–8°C 3 vials
HRP-Secondary HRP7832 12/2025 2–8°C 5 vials

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added documentation templates and optimized blocking step Annual review
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for Testing of Recovered Solvents for Reuse – V 2.0
Next Post: SOP for Verification of Raw Material Batch Number Before Issuance – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version